ArticleEULAR rheumatology open2026

Maintained improvement in patient-reported outcomes in early axial spondyloarthritis following certolizumab pegol dose reduction: findings from the randomised period of a phase 3b trial.

Antoni Chan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.